Role of surgical staging and adjuvant treatment in uterine serous carcinoma.
OBJECTIVE
This study evaluates the association of clinical and pathologic characteristics of patients with uterine serous carcinoma (USC) with disease recurrence.


METHODS
Surgically-staged patients with USC at a single institution were identified and clinical and pathologic variables were compared.


RESULTS
Of the 51 patients included in this analysis, 75% percent received adjuvant chemotherapy, 51% received radiation therapy, and 47% received both. After a median follow-up of 33 months, 42% of patients had disease recurrence. On multivariable analysis, positive pelvic lymph nodes were associated with a shorter interval between surgery and recurrence: 13.6 months progression-free survival (PFS) with positive vs 17.2 months with negative lymph nodes (p = 0.05). Patients with early-stage disease who did not receive any adjuvant treatments had a significantly greater risk of disease recurrence (44.4% vs 7.70%, p = 0.043).


CONCLUSIONS
In this population of surgically-staged patients with USC, pelvic lymph node metastases were predictive of a shorter PFS.
Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, NY, USA.
M K
MK
Frey
Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, NY, USA.
S
S
Bashir
Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, NY, USA.
N M
NM
Ward
Department of Pediatrics, Division of Infectious Diseases, Columbia University Medical Center, New York, USA.
K J
KJ
Hensel
Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, NY, USA.
T A
TA
Caputo
Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, NY, USA.
K M
KM
Holcomb
Department of Pathology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, USA.
R
R
Baergen
Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, NY, USA.
D
D
Gupta
D000368:Aged; D017024:Chemotherapy, Adjuvant; D018284:Cystadenocarcinoma, Serous / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D012189:Retrospective Studies; D014594:Uterine Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy